Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Lymphoid 2Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Oropharyngeal Neoplasms 1

Interventions

pembrolizumab 180Cisplatin 157Radiotherapy 78Carboplatin 71Radiotherapy, Intensity-Modulated 69Cetuximab 66Magnetic Resonance Spectroscopy 64Nivolumab 63Paclitaxel 52Docetaxel 50Specimen Handling 45Radiation 35Gemcitabine 33Fluorouracil 31Surveys and Questionnaires 28Biopsy 27toripalimab 26Drug Therapy 26Platinum 25Surgical Procedures, Operative 24Standard of Care 231,2-diaminocyclohexaneplatinum II citrate 23cemiplimab 22atezolizumab 21Capecitabine 20Ipilimumab 19Chemoradiotherapy 19durvalumab 18Taxes 17Immune Checkpoint Inhibitors 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
ALX148 × Head & Neck × 1 year × Clear all
NCT05787639 2026-05-19

Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)

University of California, San Diego

Phase 2 Active not recruiting
29 enrolled
Head & Neck

Oropharyngeal Neoplasms

NCT04675333 2025-08-03

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

ALX Oncology Inc.

Phase 2 Active not recruiting
172 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04675294 2025-08-01

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

ALX Oncology Inc.

Phase 2 Active not recruiting
189 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡